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In this issue, Macal et al. (2012); Walsh et al. (2012), and Wang et al. (2012) examine how adaptive immune
responses to acute and chronic lymphocyte choriomeningitis virus infection are regulated by type 1 inter-
feron produced early during infection by different cell types upon activation by intracellular nucleic acid
sensors.Chronic virus infection causes and is
maintained by dysregulation of many
mechanisms of innate resistance and
adaptive immunity. Type 1 interferon (IFN)
mediates potent antiviral and immunoreg-
ulatory mechanisms, and viruses often
target the pathways of IFN induction or
cellular signaling in order to replicate and
survive in the host. Lymphocyte chorio-
meningitis virus (LCMV), a negative strand
RNA virus, is the prototypicmember of the
arenavirus family that includes many
human pathogens. In immunocompetent
mice, acute infection with the LCMV
Armstrong (Arm) strain induces within
a week a robust CD8+ T cells response
that terminates the infection. Unlike
the aggressive Arm strain, fast-growing
variant clones with altered tropism such
as Clone 13 (Cl 13) and Docile were ob-
tained from virus isolated from chronically
infected mice inoculated with wild-type
(WT) LCMV as newborns. These variant
viruses induce systemic infections that
persist more than 90 days and are associ-
atedwith immunosuppressionof theCD8+
T cell response (clonal exhaustion). Infec-
tion with both aggressive and persistent
LCMV strains rapidly induces a type 1
IFN response that subsides after a couple
of days, due to the ability of LCMV to
decrease the number of IFN-producing
cells and to block the IFN regulatory factor
3 (IRF-3) activation pathway and IFN
production via expression of the viral
nucleoprotein (Martı´nez-Sobrido et al.,
2006). Type 1 IFN is important in the resis-
tance toLCMVnot onlybecauseof its anti-
viral activity but particularly for its role in
sustaining CD4+ and CD8+ T cell-medi-
ated immune responses.
Most cell types produce type 1 IFN in
response to virus infection through a clas-sical IFN induction pathway that it is now
known to rely on nucleic acid cytoplasmic
sensors including, among others, the
members of the helicase family RIG-I
and MDA5. However, a specialized IFN-
producing cell type, the plasmacytoid
dendritic cell (pDC), is able to rapidly
produce large amounts of type 1 IFN in
response to both infectious and inacti-
vated viruses (Colonna et al., 2004).
pDCs utilize a unique mechanism for IFN
induction involving retarded internaliza-
tion of viruses into endocytic vesicles
where they activate Toll-like receptors
(TLR) 7 and 9, recognizing RNA and DNA
sequences, respectively (Colonna et al.,
2004). In certain virus infections, e.g.,
mouse cytomegalovirus (MCMV), pDCs
are responsible for the bulk of early IFN
production upon infection, although even-
tually other mechanisms are activated
and play an important role in antiviral
resistance. The identification of the cell
types producing IFN in response to
LCMV has been controversial following
the original report that pDCs are not
important for IFN production at its peak
at 48 hr post infection (p.i.) (Dalod et al.,
2002), and subsequent studies showing
that pDC are also playing an important
and possibly major role in LCMV infec-
tion-induced IFN (Cervantes-Barragan
et al., 2012; Jung et al., 2008; Montoya
et al., 2005). However, the apparently
contradictory results can be explained
by differences in the experimental proto-
cols utilized. The Zuniga laboratory
(Macal et al., 2012) now reports that
LCMV Cl 13 productively and preferen-
tially infects pDCs due to greater binding
of virus glycoproteins to these cells than
to other hematopoietic cell types. In-
fected pDCs produced large levels ofCell Host & Microbetype 1 IFN and other cytokines including
IL-12 in a TLR7-dependent manner
(Macal et al., 2012). However, on day 1
of in vivo infection, the majority of IFN
was produced by nonproductively in-
fected pDCs, whereas the production of
IFN by other splenic cell types was strictly
limited to productively infected cells, con-
firming the unique ability of pDCs to
produce IFN in response to noninfectious
virus (Colonna et al., 2004). As in previous
studies (Cervantes-Barragan et al., 2012;
Jung et al., 2008; Montoya et al., 2005),
pDCs play an important role in the early
production of IFN in LCMV infection.
However, caution should be used when
extrapolating results from ex vivo isolated
spleen cells to the in vivo response to
virus infection. Indeed, it has been shown
that IFN production in response to viruses
such as LCMV that may utilize IFN
sources other than pDC requires intact
splenic marginal zone architecture, and
ex vivo isolation of single IFN-producing
cell suspensions may be difficult (Louten
et al., 2006). Viruses relying heavily on
pDCs, such as MCMV, are not dependent
on intact marginal zones for IFN induction
(Louten et al., 2006). Thus, the effect of
in vivo pDC depletion or inactivation on
systemic IFN levels may provide a more
quantitative evaluation of the role of
this cell type in IFN production in infec-
tions. Indeed, IFN production induced
by LCMV infection was only partially
decreased by pDC depletion or in Tlr7/
mice at 16–24 hr and was completely
normal at day 2, a time point in which
IFN production was largely abrogated in
Mda5/ mice (Walsh et al., 2012; Wang
et al., 2012). Thus, previous studies and
the three papers in this issue combined
allow us to conclude that pDCs are in11, June 14, 2012 ª2012 Elsevier Inc. 553
Figure 1. Innate and Adaptive Immune Responses to Persistent LCMV Infection
In mice infected with LCMV, type 1 IFN is produced at 16–24 hr p.i. prevalently by TLR7 expressing pDC
that are also preferentially infected. At day 2 p.i., however, most of the type 1 IFN originated from cell types
other than pDC that require intact marginal zone architecture for optimal IFN production and mostly utilize
the cytoplasmic sensor MDA5. By day 3–4 p.i. most type 1 IFN production subsides. LCMV induces
a strong CD8+ T cell response that with aggressive LCMV strains such as Arm is sufficient for controlling
the responsewithin a few days. However, infection by docile strains such as Cl 13 provokes only a reduced
CD8+ T cell response that undergoes exhaustion and contraction resulting in long-term persistence of
a poorly controlled chronic infection especially in nonhematopoietic organs. Plasmacytoid DC depletion
has little effect on the LCMV infection. Although absence of TLR7 has only an early and limited inhibiting
effect on type 1 IFN production, it results in prolonged persistence of Cl 13 expression due to defective
CD8+ T cell and B cell response that may be at least in part independent from the role of TLR7 in activation
of pDC and type I IFN production. Absence of MDA5 decreases production of type 1 IFN and reduces the
strength and accelerates the exhaustion of the CD8+ T cell response to both LCMV Arm and Cl 13 strains,
and renders the CD8+ T response to Arm dependent on CD4+ T cell help. Treatment of Cl 13-infectedmice
with exogenous IFN at day 3–4 p.i., the time at which the endogenous type 1 IFN response subsides,
strengthens the immune response in WT mice, and corrects the deficient response in Mda5/mice, pre-
venting CD8+ T cells exhaustion and dramatically shortening virus persistence.
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1 of infection but that, already at day 2, the
bulk of IFN is produced by cell types other
than pDCs (Figure 1). It remains to be
demonstrated whether—due to temporal
or spatial difference in IFN production by
different cell types during LCMV infec-
tion—the source of IFN may affect the
various antiviral and immunoregulatory
effects of type 1 IFN.
Depletion of pDCs using diphtheria
toxin treatment of a mouse strain ex-
pressing diphtheria toxin receptor under
a pDC specific promoter did not signifi-
cantly affect the T cell response or virus
persistence in mice infected with either
Arm or Cl 13 (Wang et al., 2012). These
results contrast sharply with a recent
study (Cervantes-Barragan et al., 2012)
showing that mice lacking pDCs because
of a DC-specific deletion of the transcrip-
tional factor E2-2 failed to clear a persis-
tent LCMV infection in hematopoietic
organs. These mice showed defective554 Cell Host & Microbe 11, June 14, 2012 ªCD4+ helper T cell and antiviral CD8+
T cell response; type 1 IFN was required
for both T cell responses, but pDCs
were only essential for the CD4+ helper
T cell response (Cervantes-Barragan
et al., 2012). This discrepancy can prob-
ably be explained by the fact that in the
latter study high-dose infection with the
LCMV strain Docile was used that, unlike
Cl 13, induces an almost complete elimi-
nation of precursor cytotoxic CD8+
T cells and is completely dependent on
helper T cells for host resistance (Batte-
gay et al., 1994).
pDC produce type 1 IFN in response to
LCMV via a TLR7/MyD88 pathway (Macal
et al., 2012). Tlr7/mice are fully compe-
tent in eliminating acute LCMV Arm infec-
tion but fail to eliminate a persistent
Cl 13 infection (Walsh et al., 2012). The
response of Tlr7/ mice to Cl 13 is
characterized by decreased function
and accelerated exhaustion of antiviral
T cells as well as profoundly decreased2012 Elsevier Inc.B cell responses and antibody production
(Figure 1). However, because these mice
have only an early and partial deficiency
in type 1 IFN production in response to
LCMV, the effects of the TLR7 deficiency
may be either type 1 IFN or pDC indepen-
dent. Indeed, the deficient B cell response
was shown to be due to an intrinsic effect
of TLR7 expression in the B cells, while
TLR7 expression was not required on
T cells. Interestingly, TLR7 sufficient-
memory T cells could not protect Tlr7/
mice from Cl 13 infection (Walsh et al.,
2012). Thus, a TLR7-deficient environ-
ment cannot sustain the antiviral effect
of WT CD8+ T cells, although pDC are
unlikely players in establishing an environ-
ment conductive for antiviral resistance
because pDC depletion has no effect on
Cl 13 persistence (Wang et al., 2012).
These studies contrast with the conclu-
sions of a previous study showing that
type 1 IFN production in acute LCMV
infection required a MyD88-dependent
but surprisingly TLR7-independent acti-
vation of pDC that was needed for pre-
venting virus persistence (Jung et al.,
2008). However, the latter study used
LCMVWE strain that, unlike Arm, induces
only a transient peak of type 1 IFN
production at 24 hr—a time in which
pDC are expected to contribute to IFN
production—that subsides almost com-
pletely at 48 hr, suggesting that the WE
strain has very different kinetics of acute
infection than Arm or that it fails to acti-
vate alternative IFN-producing cell type,
thus highlighting the role of pDC.
Mda5/ mice, although almost com-
pletely unable to produce type 1 IFN at
day 2 or later times after infection with
either ArmorCl 13, only showed adelayed
elimination of Arm with some detection of
LCMV glycoprotein transcripts still
observed at 64 days, unlike in WT mice
(Wang et al., 2012). CD8+ T cell amplifica-
tion as well as the clonal contraction were
delayed in Mda5/ mice, and the cells
expressed lower-activation markers and
a phenotype associated with exhaustion,
such as a slightly reduced ability to
produce cytokines and increased expres-
sion of PD-1. However, whereas in WT
mice the immune resistance to Arm is
CD4 independent,Mda5/mice showed
a strong requirement for CD4+ T cell help.
CD4+ T cell depletion in these animals re-
sulted in high virus persistence at 32 days,
reduced response of CD8+ T cells with
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reduced ability to produce TNF and
IFN-g. In mice infected with Cl 13 the
absence of MDA5 results in a decrease
in the number of activated CD8+ T cells
and increased exhaustion compatible
with the impairment of CD4+ T cell help
induced by Cl 13 (Wang et al., 2012)
(Figure 1).
Exogenous type 1 IFN treatment of WT
or Mda5/ mice dramatically improved
the CD8+ T cell response, prevented
clonal exhaustion, and induced an early
termination of Cl 13 infection with
complete disappearance of splenic virus
load at day 32 p.i. (Wang et al., 2012)
(Figure 1). Thus, IFN treatment corrected
the deficient antiviral response in the
Mda5/ mice and also improved that of
WT mice. CD4+ T cell help was not
required in the presence of optimal levels
of IFN (Wang et al., 2012). IFN treatment
was effective when administered at day
3–4, at the time in which Cl 13-infected
mice terminate their type 1 IFN response,
earlier than observed with aggressive
strains such as Arm (Wang et al., 2012).
Treatment beyond a week p.i. was
completely ineffective. These resultsshow that early exposure of CD8+ T cells
to IFN improves their expansion and
survival and primes them for resistance
to clonal exhaustion. In addition to the
direct IFN effect on CD8+ T cells
(Kolumam et al., 2005), variation in early
virus load due to the enhanced T cell
response or the direct antiviral effect of
IFN or an effect of IFN on the crosspre-
sentation of viral antigens could also
play a role in the efficacy of the treatment.
The data presented in the three papers
in this issue not only greatly contribute to
the understanding of the role of IFN,
pDCs, and nucleic acid sensors in the
immune response to LCMV but also
provide important knowledge for the
understanding of the immune pathology
of other viral chronic infections and their
treatment.
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The recent re-emphasis on malaria eradication has made developing drugs that block transmission and
terminate latent disease critical. Most drugs do not affect the liver stages—an ability that is crucial to the latter
goal. Addressing this problem, Hoepfner et al. (2012) uncover the parasite’s lysyl-tRNA synthetase as a
druggable target.Malaria is a devastating global health
problem affecting millions of people and
claiming hundreds of thousands of lives
every year, primarily African children
younger than 5 years. Although the overall
burden of the disease peaked around
2004 and has declined in the last decade,
the statistics are still grim (Murray et al.,
2012). Recently, eradication has beenadvocated again by the Bill and Melinda
Gates Foundation and the World Health
Organization (Roberts and Enserink,
2007). The Plasmodium parasite causing
malaria is vectored between humans
through mosquito bites. Most deaths
are attributable to P. falciparum, one of
the five Plasmodium species infecting
humans, but high morbidity of P. vivax,which can cause dormant liver-stage
infections, also accounts for the enor-
mous economic burden. Current control
strategies include both therapeutic and
prophylactic chemotherapy and the
blocking of transmission using vector
control including insecticide-impregnated
bed nets. Achieving eradication would be
eased by the availability of effective drugs11, June 14, 2012 ª2012 Elsevier Inc. 555
